ReviewMolecular therapy. Oncology2026
Pediatric AML CAR T cell therapy.
Review in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute myeloid leukemia (AML) is the second most common leukemia in children. Although survival rates have improved over several decades, for patients with high-risk or chemotherapy-refractory AML, hematopoietic stem cell transplantation (HSCT) remains the only curative therapy. HSCT provides immune-mediated control of residual leukemia through the graft-versus-leukemia effect, underscoring the importance of allogeneic immune responses in achieving durable remission for children with AML. Chimeric antigen receptor (CAR) T cells are genetically engineered T lymphocytes that express synthetic receptors combining antigen recognition with T cell activation and costimulatory signaling domains. By recognizing tumor antigens independently of MHC, CAR T cells can mediate potent cytotoxicity. CD19-directed CAR T cells have transformed outcomes for pediatric patients with relapsed or refractory B cell acute lymphoblastic leukemia but translating CAR T cell therapy to AML has proven challenging. This review summarizes clinical experiences to date with AML-directed CAR T cells, highlighting pediatric data. We also review barriers to successful translation of AML CAR T cell therapy that have been identified in basic and translational studies. Finally, we discuss emerging strategies to improve efficacy, including advanced CAR designs, optimized antigen and patient selection, and rational combination approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.